The Bêne Baby Company LLC Earns Wisconsin’s Patent of the Month for Pioneering Infant Formula Innovation

The United States Patent and Trademark Office recently issued Patent No. 12,616,233 to The Bêne Baby Company LLC for its groundbreaking invention titled “Infant formula composition and methods of manufacture.” Granted on May 5, 2026, this patent represents a monumental step forward in pediatric nutrition and domestic dairy processing technology.

Invented by co-founders Dr. Nikos Linardakis and Dr. James Esselman, the proprietary development delivers a premium, goat’s milk-based alternative designed to mirror the complex nutritional profile of human breast milk. By providing an entirely American-made option for toddlers aged 12 months and older, this formula establishes a new standard for quality and accessibility in the infant nutrition market.

Why This Infant Formula Invention is Highly Innovative

Traditional cow’s milk-based infant formulas frequently present digestive challenges for developing infants, often leading to sensitivities, fussiness, or allergic reactions. The Bêne Baby Company’s patented formula addresses these widespread issues by introducing several critical innovations:

• Superior Digestibility: Goat’s milk naturally forms much softer, looser curds within an infant’s stomach compared to cow’s milk. This is achieved due to significantly lower levels of the allergenic alpha-S-1-casein protein and an abundance of the beneficial alpha-S-2-casein protein, offering exceptional hypoallergenic qualities.
• Optimized Fat Structure: The formula utilizes the smaller fat molecules and high concentrations of medium-chain triglycerides (MCTs) inherent in goat’s milk, which facilitate faster and more efficient absorption of essential nutrients by an immature gastrointestinal tract.
• Elimination of Synthetic Additives: Moving away from industry norms that rely heavily on corn syrup solids, processed sugars, or palm oil, this composition prioritizes clean, natural ingredients to minimize adverse long-term metabolic health outcomes.
• Comprehensive Fortification: The formulation is precisely fortified with arachidonic acid (ARA) and docosahexaenoic acid (DHA) to promote optimal brain and ocular development, alongside vital micronutrients such as Vitamin D for bone growth, Vitamin K for the circulatory system, Vitamin B12 for neurological support, and iron for oxygen transport.

Winning Wisconsin’s June 2026 Patent of the Month

Recognized for its immense economic, agricultural, and societal value, this invention proudly captured the title of Wisconsin’s “Patent of the Month” for June 2026. Headquartered in Nekoosa, Wisconsin, The Bêne Baby Company LLC represents the best of the state’s deep-rooted dairy legacy. The patent won this prestigious distinction due to several key factors:

• Strengthening National Supply Chains: In the wake of historic national baby formula shortages driven by massive facility recalls and single-source dependencies, this patented method secures a highly resilient, 100 percent domestically manufactured supply chain right in America’s Heartland.
• Agricultural Innovation and Diversification: The invention creates an incredibly profitable, value-added market for local dairy operations. By partnering with award-winning regional creameries like the LaClare Family Creamery in Malone, Wisconsin, the company enables traditional bovine farmers to diversify or convert to dairy goat farming, injecting vital economic growth into rural communities.
• Small-Batch Quality Assurance: The patented manufacturing methodology leverages specialized local powdering processes that allow for strict, batch-by-batch tracking, ensuring the ultimate level of purity, safety, and compliance with federal food standards.

U.S. R&D Tax Credit Eligibility for Practical Applications

The development and implementation of the practical applications outlined in this patent present a clear pathway for utilizing the United States Research and Development (R&D) Tax Credit under Internal Revenue Code Section 41. To qualify under the four-part test, a company must demonstrate that its activities are technological in nature, eliminate technical uncertainty, involve a process of experimentation, and serve a permitted purpose of improving product performance or manufacturing quality. In this scenario, the qualified research expenses (QREs) can include the wages paid to food scientists, chemists, and medical professionals who engineered the exact enzymatic balances and nutritional matrices. Additionally, the costs associated with iterative small-batch testing, stabilization of goat-milk powders without synthetic sugars, and clinical trials to ensure compliance with stringent Food and Drug Administration (FDA) regulations represent eligible experimental costs. By capturing these substantial design and process engineering expenditures, the company can significantly reduce its federal and state tax liabilities, reinforcing the financial viability of domestic manufacturing innovations.